Have a personal or library account? Click to login
Case report of nasal pseudotumor – a rare presentation in severe haemophilia A with high titre inhibitors Cover

Case report of nasal pseudotumor – a rare presentation in severe haemophilia A with high titre inhibitors

Open Access
|Mar 2021

Figures & Tables

A case report from Kolkata, India, highlights the possibility of treating a high titre inhibitor with rituximab, and the identification of a pseudotumor as the cause of epistaxis.
A case report from Kolkata, India, highlights the possibility of treating a high titre inhibitor with rituximab, and the identification of a pseudotumor as the cause of epistaxis.

Figure 1

A. Swelling at the root of nose and forehead after trauma due to fall; B. Nasal swelling persisted and gradually started increasing in size; C. CT scan showing a lobulated expansile soft tissue mass in the bilateral anterior nasal space; D. The soft tissue mass was excised –grossly there were only old clots inside; E. Day seven post-operatively, the child did not have any further bleeding episodes; F. The child has been under regular follow-up for the last three years and is on continued prophylaxis.
A. Swelling at the root of nose and forehead after trauma due to fall; B. Nasal swelling persisted and gradually started increasing in size; C. CT scan showing a lobulated expansile soft tissue mass in the bilateral anterior nasal space; D. The soft tissue mass was excised –grossly there were only old clots inside; E. Day seven post-operatively, the child did not have any further bleeding episodes; F. The child has been under regular follow-up for the last three years and is on continued prophylaxis.
DOI: https://doi.org/10.17225/jhp00172 | Journal eISSN: 2055-3390
Language: English
Page range: 11 - 14
Published on: Mar 3, 2021
Published by: Haemnet Ltd
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2021 Prakas Kumar Mandal, Malini Garg, Debasis Gantait, Utpal Jana, published by Haemnet Ltd
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.